



**NeuroScientific**  
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway  
Nedlands WA 6009 Australia

12 November 2018

The Manager  
ASX Market Announcements  
Australian Securities Exchange  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

**Electronic Lodgement**

**NeuroScientific Biopharmaceuticals Limited  
Pro-Rata Non-Renounceable Entitlement Issue**

Dear Sir / Madam

Please find attached a letter that will be distributed to eligible shareholders today regarding the non-renounceable entitlement issue announced on 9 November 2018.

Yours faithfully

Thomas Spencer  
Company Secretary

12 November 2018



Dear Shareholder

### NeuroScientific Biopharmaceuticals Ltd – Pro-Rata Non-Renounceable Entitlement Issue

On 9 November 2018, NeuroScientific Biopharmaceuticals Ltd (ACN 102 832 995) (**Company**) lodged a prospectus with the ASIC and the ASX (**Prospectus**) for a non-renounceable entitlement issue of two (2) Options for every five (5) Shares to raise approximately \$294,322 (**Offer**). The issue price of Options under the Offer is \$0.01 each.

The Options will be exercisable at \$0.20 each on or before 7 March 2021. Further details of the terms and conditions of the Options are set out in section 6.1 of the Prospectus.

The funds raised from the Offer are planned to be used in accordance with the table set out below:

Proceeds of the Offer	Full Subscription (\$)	%
Working capital	\$269,322	91.5%
Expenses of the Offer	\$25,000	8.5%
<b>Total</b>	<b>\$294,322</b>	<b>100.00%</b>

The Offer is being made to all shareholders of the Company (**Shareholders**) named on its register of members at 5:00pm (WST) on 15 November 2018, whose registered address is in Australia or New Zealand.

Following completion of the Offer, the Company will have issued approximately 29,432,237 Options resulting in total Options on issue of approximately 65,432,237.

A copy of the Prospectus is available on ASX's and the Company's website. Eligible Shareholders will be mailed a Prospectus together with an Entitlement and Acceptance Form no later than 20 November 2018. Your entitlement will be set out on the personalised Entitlement and Acceptance Form accompanying the Prospectus.

For the purposes of calculating each Eligible Shareholders' entitlement, fractions of entitlements have been rounded up to the nearest whole number of Options.

### Actions required of Eligible Shareholders

There are a number of actions Eligible Shareholders may take:

- You may wish to accept all of your rights to subscribe for Options pursuant to the Prospectus (**Entitlement**). To take up all or some of your Entitlements you will need to ensure your application money for the Entitlements you wish to take up is received by Automic (**Share Registry**) by no later than 5:00pm (WST) on 29 November 2018, by completing and returning your Entitlement and Acceptance Form together with your cheque, drawn on an Australian bank or bank draft made payable in Australian currency, for the amount indicated on the Entitlement and Acceptance Form or by making a payment by BPAY in accordance with the instructions on your Entitlement and Acceptance Form.
- You may wish to accept part of your Entitlement. To take up part of your Entitlement you will need to ensure your application money for the Entitlements you wish to take up is received by the Share Registry by no later than 5:00pm (WST) on 29 November 2018, by completing and returning your Entitlement and Acceptance Form by filling in the number of Options you wish to accept in the space provided on the Entitlement and Acceptance Form together with your cheque, drawn on an Australian bank or bank draft made payable in Australian currency, for the appropriate application

monies or by making a payment by BPAY in accordance with the instructions on your Entitlement and Acceptance Form (at \$0.01 per Option).



**NeuroScientific**  
BIOPHARMACEUTICALS

- You may do nothing. If you choose to do nothing with your Entitlements, while you will continue to hold the same number of Options, your interest in the Company will be diluted and you will receive no value for your Entitlement.

#### Key dates for the Offer

Event	Proposed Date
Lodgement of Prospectus with the ASIC	9 November 2018
Lodgement of Prospectus & Appendix 3B with ASX	9 November 2018
Notice sent to Optionholders	9 November 2018
Notice sent to Shareholders	13 November 2018
Ex date	14 November 2018
Record Date for determining Entitlements	15 November 2018
Prospectus despatched to Shareholders & Company announces despatch has been completed	20 November 2018
Closing Date*	29 November 2018
Securities quoted on a deferred settlement basis	30 November 2018
ASX notified of under subscriptions	4 December 2018
Issue date, despatch of holding statements and deferred settlement trading ends	6 December 2018

\* The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date. As such the date the Options are expected to commence trading on ASX may vary.

If you have any queries concerning the Offer, or the action you are required to take to subscribe for Options, please contact your financial adviser or Thomas Spencer, the Company Secretary, on +61 8 6382 1800.

Yours sincerely

Mr Matthew Liddelow  
CEO

#### Contact details:

Matthew Liddelow  
CEO  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)  
+61 8 6382 1805

Thomas Spencer  
CFO & Company Secretary  
[ir@neuroscientific.com](mailto:ir@neuroscientific.com)  
+61 491 108 250